Back to News
Market Impact: 0.12
Satellos Names Forazapadin As INN For Lead DMD Drug Candidate
Source: Nasdaq
Healthcare & BiotechProduct Launches
Satellos Bioscience announced that the World Health Organization assigned the INN forazapadin to its lead drug candidate, formerly designated SAT-3247. The naming milestone formalizes the candidate's nonproprietary identity but does not include clinical, regulatory, or financial updates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
MSCL0.00
More News
- Samsung works to draw iPhone users to its foldables even as Apple enters the market
- Oil Tops $100 on Supply Fears, Apple Faces a Big Test
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights
- Apple drops its folding iPhone. Our first reaction, plus the other key launch news